These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31718458)

  • 21. Survival trial design and monitoring using historical controls.
    Wu J; Xiong X
    Pharm Stat; 2016 Sep; 15(5):405-11. PubMed ID: 27307025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stepwise progressive parametric multiple testing procedure with correlated normal test statistics.
    Deng X; Chang M
    J Biopharm Stat; 2020 May; 30(3):550-563. PubMed ID: 32191556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.
    Hartung J
    Biom J; 2006 Aug; 48(4):521-36. PubMed ID: 16972703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous sequential monitoring of efficacy and safety led to masking of effects.
    van Eekelen R; de Hoop E; van der Tweel I
    J Clin Epidemiol; 2016 Aug; 76():155-65. PubMed ID: 26944293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
    Asakura K; Hamasaki T; Evans SR
    Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A note on sequential monitoring of select-the-winner design.
    Lan KK; Chen F; Zhong B; Shun Z
    J Biopharm Stat; 2015; 25(3):408-16. PubMed ID: 25645054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A group sequential test for treatment effect based on the Fine-Gray model.
    Martens MJ; Logan BR
    Biometrics; 2018 Sep; 74(3):1006-1013. PubMed ID: 29534294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-stage designs with small sample sizes.
    Kieser M; Rauch G; Pilz M
    J Biopharm Stat; 2023 Jan; 33(1):53-59. PubMed ID: 35612521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size calculation for planning group sequential longitudinal trials.
    Liu A; Boyett JM; Xiong X
    Stat Med; 2000 Jan; 19(2):205-20. PubMed ID: 10641025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing a primary and a secondary endpoint in a group sequential design.
    Tamhane AC; Mehta CR; Liu L
    Biometrics; 2010 Dec; 66(4):1174-84. PubMed ID: 20337631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Planning and analyzing adaptive group sequential survival trials.
    Wassmer G
    Biom J; 2006 Aug; 48(4):714-29. PubMed ID: 16972724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials?
    Pressman AR; Avins AL; Hubbard A; Satariano WA
    Contemp Clin Trials; 2011 Jul; 32(4):561-8. PubMed ID: 21453792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.